KUALA LUMPUR, May 11 (Bernama) -- Mawi DNA Technologies (Mawi), a medical device company focusing on the development of innovative technologies for biosampling, has launched the NextSWAB™, a 100 per cent medical-grade plastic swab designed and manufactured in the US.
Mawi launched this new product in response to the COVID-19 swab shortage, and it is designed for high efficiency collection without the possibility of contamination from glue or fibres used in flock and cotton swabs that may inhibit PCR based assays. NextSWAB™ is currently optimised for nasal sample collection with validation for other sample types ongoing.
“The NextSWAB™ sterile sampling applicator is six inches in length with a unique head design positioned at the distal end,” said Mawi CEO, Dr Bassam El-Fahmawi in a statement.
“The swab head has two channels separated by a septum that retains the collected nasal material which can then be released into the transport media with a gentle shake. The flexible head fits into crevices with ease and effectiveness. It enables anterior nasal sample collection with minimal user discomfort sufficient for a meaningful result.
“Our NextSWAB™ fully releases its contents into the sample transport media removing the need for the swab to be transported with the sample. A fully concentrated liquid sample can then be quickly processed with robotic liquid handling systems or any laboratory workflow.”
The NextSWAB™ is compatible with many sample transport tubes making it ideal for multiple swab sample pooling in a single tube.
However, to achieve optimal results, it is most effective when used in conjunction with Mawi’s iSWAB-Microbiome-EL sample collection technology which allows users to skip the RNA extraction step in COVID-19 molecular tests.
With demand for COVID-19 sample collection swabs, the supply chain line for the NextSWAB™ is reliable and stable thanks to the plastic molded construction and USA based manufacturing.
For more information, visit http://www.mawidna.com.
-- BERNAMA
No comments:
Post a Comment